Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 20, 2021 03:30 ET | Source: CatalYm GmbH

CatalYm to Present Initial Data of First-in-Human Trial of GDF-15 neutralizing antibody CTL-002 at the 2021 ASCO Annual Meeting

MUNICH, Germany, May 20, 2021 (GLOBE NEWSWIRE) -- CatalYm GmbH, a biopharmaceutical company developing novel cancer immunotherapies, today announced that their abstract with first interim data from...
May 04, 2021 05:00 ET | Source: CatalYm GmbH

CatalYm Appoints Industry Leader Dr. Phil L’Huillier as Chief Executive Officer

MUNICH, Germany, May 04, 2021 (GLOBE NEWSWIRE) -- CatalYm GmbH, a biopharmaceutical company developing novel cancer immunotherapies, today announced the appointment of Dr. Phil L’Huillier as Chief...
November 10, 2020 03:00 ET | Source: CatalYm GmbH

CatalYm raises EUR50 million to advance GDF-15 antibody into clinical trials for checkpoint-inhibitor refractory patients

MUNICH, Germany, Nov. 10, 2020 (GLOBE NEWSWIRE) -- CatalYm GmbH, a biopharmaceutical company developing novel cancer immunotherapies, today announced the closing of its EUR50 million Series B...
June 18, 2020 10:00 ET | Source: CatalYm GmbH

CatalYm to Present Data on Targeting Novel Checkpoint GDF-15 for Immunotherapy of Cancer at the AACR Annual Meeting 2020

MUNICH, Germany, June 18, 2020 (GLOBE NEWSWIRE) -- CatalYm GmbH, a biopharmaceutical company developing novel cancer immunotherapies, today announced that two abstracts identifying a novel...